{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:11:00Z","timestamp":1789593060429,"version":"build-2803163510"},"reference-count":46,"publisher":"American Society for Clinical Investigation","issue":"7","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["ZIA BC 010944"],"award-info":[{"award-number":["ZIA BC 010944"]}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"crossref","award":["#02666"],"award-info":[{"award-number":["#02666"]}],"id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Precigen Inc","award":["#03209"],"award-info":[{"award-number":["#03209"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,8]]},"abstract":"<jats:p>\n                    There are approximately 44,000 cases of human papillomavirus\u2013associated (HPV-associated) cancer each year in the United States, most commonly caused by HPV types 16 and 18. Prophylactic vaccines successfully prevent healthy people from acquiring HPV infections via HPV-specific antibodies. In order to treat established HPV-associated malignancies, however, new therapies are necessary. Multiple recombinant gorilla adenovirus HPV vaccine constructs were evaluated in NSG-\u03b22m\n                    <jats:sup>\u2013\/\u2013<\/jats:sup>\n                    peripheral blood mononuclear cell\u2013humanized mice bearing SiHa, a human HPV16\n                    <jats:sup>+<\/jats:sup>\n                    cervical tumor, and\/or in the syngeneic HPV16\n                    <jats:sup>+<\/jats:sup>\n                    TC-1 model. PRGN-2009 is a therapeutic gorilla adenovirus HPV vaccine containing multiple cytotoxic T cell epitopes of the viral oncoproteins HPV 16\/18 E6 and E7, including T cell enhancer agonist epitopes. PRGN-2009 treatment reduced tumor volume and increased CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells in the tumor microenvironment of humanized mice bearing the human cervical tumor SiHa. PRGN-2009 monotherapy in the syngeneic TC-1 model also reduced tumor volumes and weights, generated high levels of HPV16 E6\u2013specific T cells, and increased multifunctional CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells in the tumor microenvironment. These studies provide the first evaluation to our knowledge of a therapeutic gorilla adenovirus HPV vaccine, PRGN-2009, showing promising preclinical antitumor efficacy and induction of HPV-specific T cells, along with the rationale for its evaluation in clinical trials.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.141912","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T12:01:18Z","timestamp":1614686478000},"source":"Crossref","is-referenced-by-count":25,"title":["Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009"],"prefix":"10.1172","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-4104","authenticated-orcid":true,"given":"Samuel T.","family":"Pellom","sequence":"first","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Smalley Rumfield","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Y. Maurice","family":"Morillon","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Roller","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Poppe","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Brough","sequence":"additional","affiliation":[{"name":"Precigen Inc., Germantown, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Sabzevari","sequence":"additional","affiliation":[{"name":"Precigen Inc., Germantown, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-9855","authenticated-orcid":true,"given":"Caroline","family":"Jochems","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30716"},{"key":"B2","unstructured":"Centers for Disease Control and Prevention. Cancers associated with human papillomavirus, United States. https:\/\/www.cdc.gov\/cancer\/uscs\/about\/data-briefs\/no10-hpv-assoc-cancers-UnitedStates-2012-2016.htm Accessed March 2, 2021"},{"issue":"3","key":"B3","first-page":"637","article-title":"Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review)","volume":"52","author":"Boda","year":"2018","journal-title":"Int J Oncol"},{"issue":"7","key":"B4","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/v7072802","article-title":"Human papillomaviruses; epithelial tropisms, and the development of neoplasia","volume":"7","author":"Egawa","year":"2015","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e21"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021641"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-016-0293-9"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(77)90239-2"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.24.1.108-120.1977"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(79)90110-7"},{"issue":"50","key":"B11","first-page":"7","article-title":"Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies","volume":"10","author":"Harper","year":"2010","journal-title":"Discov Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2012.744393"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.8.2.209-220.2001"},{"issue":"8","key":"B14","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.4049\/jimmunol.152.8.3904","article-title":"Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins","volume":"152","author":"Kast","year":"1994","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-1702(98)00008-2"},{"issue":"3 Suppl","key":"B16","first-page":"788s","article-title":"Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7","volume":"7","author":"Rudolf","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12620"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3033461"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<725::AID-IJC19>3.0.CO;2-K"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(10)60017-4"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-7-528"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-748","article-title":"Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive\u00ae) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer","volume":"14","author":"Sebastian","year":"2014","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.2.227"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1157477"},{"issue":"1","key":"B25","first-page":"119","article-title":"Adenoviruses isolated from wild gorillas are closely related to human species C viruses","volume":"444","author":"McVey","year":"2013","journal-title":"Virology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.142"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1911-z"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.025"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0635-8"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv063"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05608-11"},{"issue":"9","key":"B32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136654","article-title":"Polarisation of tumor-associated macrophages toward M2 phenotype correlates with poor response to chemoradiation and reduced survival in patients with locally advanced cervical cancer","volume":"10","author":"Petrillo","year":"2015","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1881"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1640-x"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.09.020"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4051"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001395"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2653"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-0970-1"},{"issue":"1","key":"B43","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res"},{"issue":"2","key":"B44","doi-asserted-by":"crossref","first-page":"e1532764","DOI":"10.1080\/2162402X.2018.1532764","article-title":"The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex","volume":"8","author":"Jochems","year":"2018","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20680"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5181"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/141912\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:44:52Z","timestamp":1779151492000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/141912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,8]]},"published-print":{"date-parts":[[2021,4,8]]}},"alternative-id":["10.1172\/jci.insight.141912"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.141912","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"article-number":"e141912"}}